| symbol |
FLKS |
|---|
| 会社名 | Flex Pharma Inc （フレックス・ファ―マ） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Major Pharmaceuticals
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Flex Pharma Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps muscle cramps and spasms associated with severe neuromuscular conditions and exercise associated muscle cramps (EAMCs). The Company''s product candidates activate certain receptors in primary sensory neurons which then act through neuronal circuits to reduce the repetitive firing or hyperexcitability of alpha-motor neurons in the spinal cord thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps muscle cramps spasms and spasticity associated with severe neuromuscular conditions and exercise-associated muscle cramps segment. The Company''s lead drug product candidate is FLX-787 which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs. フレックス・ファ―マは開発段階の米国のバイオテクノロジ―企業。重度の神経筋に伴う夜間性の下肢痙攣治療薬の開発を手掛ける。筋痙攣とは不意に骨格筋が痛みを伴う痙攣を起こすもので、痛みが数日間続く事がある。現在米国では認可されている夜間性下肢痙攣治療薬が無い為に、同社は新薬、並びに数時間の鎮痛効果のある栄養補助食品を開発中。 Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA.
|
|---|
| 本社所在地 | 800 Boylston Street 24th Floor Boston MA 02199 USA |
|---|
| 代表者氏名 | Christoph H. Westphal Christoph H. Westphal |
|---|
| 代表者役職名 | Chairman of the Board 取締役会会長 |
|---|
| 電話番号 | +1 617-874-1821 |
|---|
| 設立年月日 | 41671 |
|---|
| 市場名 | NASDAQ National Market System |
|---|
| ipoyear | 2015年 |
|---|
| 従業員数 | 22人 |
|---|
| url | www.flex-pharma.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/flks |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -33.69347 |
|---|
| 終値（lastsale） | 0.4725 |
|---|
| 時価総額（marketcap） | 8537827.41 |
|---|
| 時価総額 | 時価総額（百万ドル） 10.51644 |
|---|
| 売上高 | 売上高（百万ドル） 1.12051 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） -5.24053 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -34.63574 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Flex Pharma Inc revenues decreased 27% to $424K. Net loss increased 1% to $17.3M. Revenues reflect Other revenue decrease of 10% to $6K. Higher net loss reflects Drug Development segment loss increase of 39% to $10.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.00 to -$0.96. |
|---|
FLKS - フレックス・ファ―マ （Flex Pharma Inc.） フレックス・ファ―マ